Tag: GDP

Managing Uncontrolled Hybrid Paper-Electronic Workflows During System Upgrades During system upgrades, the integrity of hybrid paper-electronic workflows can often become compromised, leading to potential non-compliance and data integrity issues. In…

Mitigating Weak System Access Controls During Validation Lifecycle: A CAPA Playbook In an era of heightened regulatory scrutiny, pharmaceutical companies are increasingly faced with challenges related to system access controls…

Addressing Record Retention Failures in the Validation Lifecycle and Developing a CAPA Strategy Record retention failures during the validation lifecycle are a pressing concern for pharmaceutical professionals. From production to…

Uncontrolled Hybrid Paper-Electronic Workflows: Compliance Gaps and Resolutions In today’s pharmaceutical landscape, the convergence of paper and electronic workflows presents unique challenges regarding compliance with 21 CFR Part 11. Pharmaceutical…

Managing Uncontrolled Hybrid Paper-Electronic Workflows During System Upgrades The rapid digital transformation in pharmaceutical operations has fostered hybrid workflows that combine paper and electronic systems. However, improperly managed transitions can…

Managing Uncontrolled Hybrid Paper-Electronic Workflows During Validation to Prevent Part 11 Findings In the rapidly evolving landscape of pharmaceutical manufacturing and regulatory compliance, addressing the challenges posed by hybrid paper-electronic…

Preventing Repeat Findings from Record Retention Failures in Compliance Audits During compliance audits, record retention failures can trigger non-compliance issues, particularly related to 21 CFR Part 11 regarding electronic records.…

Strengthening System Access Controls Throughout the Validation Lifecycle Pharmaceutical companies often face challenges related to system access controls, particularly during the validation lifecycle. Weak access controls can lead to significant…

Strategies for Addressing ERES Control Failures During Inspection Walkthroughs When regulatory inspectors notice lapses in electronic records and electronic signatures (ERES) controls during walkthroughs, it poses a significant risk for…

Preventing Record Retention Failures During Inspection Walkthroughs In the highly regulated pharmaceutical industry, maintaining adequate record retention practices is crucial for compliance during inspections. Given the heightened scrutiny from regulatory…

Addressing Compliance Gaps in Electronic Signature Use During System Operation The use of electronic signatures in pharmaceutical manufacturing and quality control envelops critical regulatory compliance under 21 CFR Part 11.…

“`html Addressing Misuses of Electronic Signatures During System Operation: A Practical Guide In today’s digital age, the misuse of electronic signatures during system operation is an increasingly pressing issue for…